Quick Answer
Phathom Pharmaceuticals, Inc. reported Operating Income of -$159.99 million for fiscal year 2025.
Phathom Pharmaceuticals, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$159.99M | +42.3% |
| 2024 | -$277.47M | -65.8% |
| 2023 | -$167.31M | +3.0% |
| 2022 | -$172.44M | -27.7% |
| 2021 | -$135.08M | -7.5% |
| 2020 | -$125.67M | -18.3% |
| 2019 | -$106.22M | -8570.6% |
| 2018 | -$1.23M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$15.27M | +78.4% | +74.5% |
| June 30, 2025 | -$59.92M | +22.5% | +24.0% |
| March 31, 2025 | -$78.86M | -12.7% | -11.4% |
| September 30, 2024 | -$70.80M | -98.5% | +8.4% |
| June 30, 2024 | -$77.30M | -143.8% | -10.5% |
| March 31, 2024 | -$69.95M | -132.6% | -96.2% |
| September 30, 2023 | -$35.66M | +16.2% | -12.5% |
| June 30, 2023 | -$31.70M | +30.1% | -5.4% |
- Phathom Pharmaceuticals, Inc. showed an increase of +42.3% in Operating Income compared to the prior fiscal year.
- Over the 2018–2025 period, Phathom Pharmaceuticals, Inc.’s operating income has declined by 12960.1% (from -$1.23 million to -$159.99 million).
- The most recent figure is from Phathom Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: